Pharmala Biotech Holdings Inc (MDXXF)

$0.07 -0.01 (-15.81%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol 27,240
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

Industry: Biotechnology
Sector: Healthcare
Website: pharmala.ca
Address:
1055 West Georgia Street, P.O. Box 11117, Vancouver, Canada
Manudonuts
Manudonuts Apr. 25 at 1:28 PM
$MDXXF https://x.com/us_fda/status/2047689418559856820?s=46&t=nzbNBsJ65Dc3qwnt-1LDtw
0 · Reply
Manudonuts
Manudonuts Apr. 25 at 1:27 PM
$MDXXF
0 · Reply
Sigsig
Sigsig Apr. 21 at 6:48 PM
$MDXXF / $MDMA.CN, $PHRM.CN/$PHRRF, $OPTHF / $OPTI.CN,
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:41 PM
$MDXXF 2024 (Scaling and validation) • Continued repeat shipments to Australia, confirming recurring revenue potential. • Strengthened position as a first-mover supplier in a legal MDMA treatment market globally. • Advanced clinical collaborations and research supply agreements (North America and international). Strategic significance • Transitioned from concept → regulated supplier with real sales. • Established first commercial MDMA supply chain into a legal psychiatric market (Australia). • Positioned as a picks-and-shovels player in the psychedelic sector (lower clinical risk vs drug developers, but dependent on regulatory adoption).
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:41 PM
$MDXXF 2022 (Regulatory and commercialization breakthroughs) • Became one of the first companies to legally sell MDMA for a patient treatment under Canada’s Special Access Program (SAP). • Secured controlled substance dealer’s license in Canada. • Initiated international export pathways for MDMA. 2023 (Major inflection point – Australia) • Australia rescheduled MDMA (July 2023) to allow prescription use for PTSD. • PharmAla became a primary supplier of MDMA to authorized Australian psychiatrists, effectively entering a commercial therapeutic market. • Completed multiple international shipments of MDMA (Canada → Australia), demonstrating regulatory execution. • Expanded partnerships with clinics and distributors (e.g., Vitura Health).
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:27 PM
$MDXXF https://pharmala.ca/media/2026/04/pharmala-biotech-positioned-to-supply-u-s-expanded-access-pathway-for-mdma-established-by-presidential-executive-order
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:21 PM
$MDXXF US still sleeping. Fireworks incoming
0 · Reply
SmallCapWealth
SmallCapWealth Apr. 20 at 1:52 PM
$MDXXF This is going to explode
0 · Reply
LOLROFLMAO
LOLROFLMAO Dec. 10 at 2:36 PM
$MDXXF PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules https://pharmala.ca/media/2025/12/pharmala-biotech-completes-release-testing-on-australian-made-laneo-capsules
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 24 at 1:25 PM
$MDMA.CSE $MDXXF
0 · Reply
Latest News on MDXXF
No data available.
Manudonuts
Manudonuts Apr. 25 at 1:28 PM
$MDXXF https://x.com/us_fda/status/2047689418559856820?s=46&t=nzbNBsJ65Dc3qwnt-1LDtw
0 · Reply
Manudonuts
Manudonuts Apr. 25 at 1:27 PM
$MDXXF
0 · Reply
Sigsig
Sigsig Apr. 21 at 6:48 PM
$MDXXF / $MDMA.CN, $PHRM.CN/$PHRRF, $OPTHF / $OPTI.CN,
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:41 PM
$MDXXF 2024 (Scaling and validation) • Continued repeat shipments to Australia, confirming recurring revenue potential. • Strengthened position as a first-mover supplier in a legal MDMA treatment market globally. • Advanced clinical collaborations and research supply agreements (North America and international). Strategic significance • Transitioned from concept → regulated supplier with real sales. • Established first commercial MDMA supply chain into a legal psychiatric market (Australia). • Positioned as a picks-and-shovels player in the psychedelic sector (lower clinical risk vs drug developers, but dependent on regulatory adoption).
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:41 PM
$MDXXF 2022 (Regulatory and commercialization breakthroughs) • Became one of the first companies to legally sell MDMA for a patient treatment under Canada’s Special Access Program (SAP). • Secured controlled substance dealer’s license in Canada. • Initiated international export pathways for MDMA. 2023 (Major inflection point – Australia) • Australia rescheduled MDMA (July 2023) to allow prescription use for PTSD. • PharmAla became a primary supplier of MDMA to authorized Australian psychiatrists, effectively entering a commercial therapeutic market. • Completed multiple international shipments of MDMA (Canada → Australia), demonstrating regulatory execution. • Expanded partnerships with clinics and distributors (e.g., Vitura Health).
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:27 PM
$MDXXF https://pharmala.ca/media/2026/04/pharmala-biotech-positioned-to-supply-u-s-expanded-access-pathway-for-mdma-established-by-presidential-executive-order
0 · Reply
Manudonuts
Manudonuts Apr. 20 at 9:21 PM
$MDXXF US still sleeping. Fireworks incoming
0 · Reply
SmallCapWealth
SmallCapWealth Apr. 20 at 1:52 PM
$MDXXF This is going to explode
0 · Reply
LOLROFLMAO
LOLROFLMAO Dec. 10 at 2:36 PM
$MDXXF PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules https://pharmala.ca/media/2025/12/pharmala-biotech-completes-release-testing-on-australian-made-laneo-capsules
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 24 at 1:25 PM
$MDMA.CSE $MDXXF
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 24 at 1:16 PM
$MDMA.CSE $MDXXF
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 22 at 1:10 PM
$MDMA.CSE $MDXXF
0 · Reply
theflynews
theflynews Oct. 9 at 3:05 PM
Psychedelic: PharmAla launches portal for MDMA prescribers, therapists - $MDXXF - https://thefly.com/permalinks/entry.php/MDXXFid4210901?17
0 · Reply
LOLROFLMAO
LOLROFLMAO Sep. 3 at 1:38 PM
$MDXXF PharmAla Incorporates Australian Entity for Clinical Research https://pharmala.ca/media/2025/09/pharmala-incorporates-australian-entity-for-clinical-research
0 · Reply
McGuireTO
McGuireTO Aug. 5 at 2:33 PM
$MDMA.CSE $MDXXF Pharmala Biotech has set a new support level and is slowly creeping back to resistance with big bid support and orders chipping away at the key level. I'm anticipating this to get a sympathy run along with $ATAI $DFTX and $CMPS and the chart is tight enough that this can be an explosive move
1 · Reply
McGuireTO
McGuireTO Jul. 29 at 1:21 AM
$MDMA.CSE $MDXXF PharmAla Biotech Getting Very Tight, break is imminent. I have a bullish lean on this given the bullish tailwinds in the sector, the ramping up of bull volume on the weekly chart, and the lower wicks that look like accumulation to me on the monthly timeframe I post regular analysis of the psychedelics sector, please like and follow to make sure you don't miss my next update! Support: 0.090, 0.085 Resistance: 0.110, 0.115 https://www.tradingview.com/chart/MDMA/enhXzeMY-PharmAla-Biotech-Getting-Very-Tight-powerful-break-is-imminent/
0 · Reply
taxidriver514
taxidriver514 Apr. 30 at 6:28 PM
$MDXXF $MNMD.DL0126 $HELP.DL0126 $ATAI 🍄💊🤯🪖
0 · Reply
LOLROFLMAO
LOLROFLMAO Apr. 11 at 4:10 PM
$MDXXF Multiple March news...
0 · Reply